Loading

logo

Journal of Experimental Pathology

ISSN: 2694-5061

Review Article Open Access
Volume 2 | Issue 2 | DOI: https://doi.org/10.33696/pathology.2.019

Can Early Home administration of Azithromycin with Zinc Help Prevent Severe COVID-19 Disease Progression and Long-COVID?

Philippe Lepere1,*, Bruno Escarguel2, Selda Yolartiran2, Claude Escarguel3,4
  • 1University of Geneva, Institute of Global Health, 24 rue du General-Dufour 1205 Geneva, Switzerland
  • 2Saint Joseph Hospital, COVID Unit, 26 Bd de Louvain 13008 Marseille, France
  • 3Association Biologie et Cooperation, 135 Traverse du Gaou 83140 Six-Fours, France
  • 4Union Pour la Prévention et la Gestion des Crises Sanitaires, 11 rue de Tabary, 59278 Escaupont, France
+ Affiliations - Affiliations

Corresponding Author

Philippe Lepere, lepere.p@wanadoo.fr, philippe.lepere@etu.unige.ch

Received Date: April 10, 2021

Accepted Date: May 03, 2021

Citation:

 Lepere P, Escarguel B, Yolartiran S, Escarguel C. Can Early Home administration of Azithromycin with Zinc Help Prevent Severe COVID-19 Disease Progression and Long-COVID?. J Exp Pathol. 2021;2(2):75-89.


Copyright: © 2021 Lepere P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Introduction: The effects of the SARS-CoV-2 pandemic continue to disrupt health systems worldwide, leading to population lockdowns in many countries. Preventing hospitalisation, death and long-COVID with repurposed drugs remains a valuable research goal. To respond to this priority, the use of azithromycin (AZM) is one of the most common treatments worldwide, in combination with hydroxychloroquine (HCQ) or as standalone molecule. With the aim of decentralizing early treatment to family practitioners, we address the question: Can early home administration of AZM with zinc help prevent severe COVID-19 disease progression and long-COVID?

Methodology: We conducted a scoping review of articles published from 31 December 2019 to 5 November 2020 in the PubMed, Google Scholar, MedRxiv, and BioRxiv databases, and a review of ongoing clinical trials published in the Clinicaltrial.gov database.

Results: Many studies report on outpatient treatment with a combination of AZM + HCQ versus AZM alone, and a few studies propose the addition of zinc (Zn) to AZM. Studies using HCQ were not considered in this review. We failed to identify any study reporting results of home-based utilisation of AZM administrated by family practitioners. In addition, we identified seven clinical trials currently recruiting individuals for early outpatient treatment with AZM, but results have not yet been published.

Discussion: The antiviral, anti-inflammatory, immunomodulatory benefits of AZM + Zn make this drugs combination a good candidate therapy to treat flu-like COVID-19 and atypical pneumoniae. The antibacterial action of AZM is expected to disrupt the poorly-documented bacteria-virus cooperation. Considering the pros and cons of macrolide use (including antimicrobial resistance), we call for further research on the early use of this therapy by family practitioners for the home treatment of individuals presenting mild or moderate symptoms to prevent hospitalisation, death and long-COVID.

Keywords

COVID-19; Azithromycin; Early treatment; Family practitioners

Recommended Articles

COVID-19 Clinical Research

While the global COVID-19 pandemic has challenged the entire humanity and health systems, it also triggered researchers to urgently perform clinical trials to assess the safety and efficacy of many agents and modalities to combat COVID-19. As of April 22, over 650 clinical studies have been registered both in USA and internationally. Results from these studies are also coming at a brisk pace in this unprecedented emergency.

Therapeutic Values of Ketamine for COVID-19-Cared Patients: An Expert’s Point of View

Ketamine has long been used in the field of anesthesia [1]. Its rapid and long-acting analgesic effects associated with its dissociative properties have also established its use in prehospital and emergency department patients.

A Bioinformatics Protocol for Rational Design of Peptide Vaccines and the COVID-19 Rampage

The currently ongoing coronavirus pandemic, the SARSCOV- 2, interchangeably referred to as the COVID-19 infection, has in a short span of time altered the ways and means of almost all of mankind. So strong has been its effect that all human activity ceased in one way or another for a considerable time, led to significant loss of life and economic drain of.

Lessons Learnt from COVID-19: How Can We Prepare for Another Pandemic?

Five months into the COVID-19 pandemic, the U.S. death toll from the virus has now surpassed 100,000 people. Many more cases remain nationwide, while an unknown number of patients currently harbor the virus asymptomatically. While health officials are now optimistic regarding the decline in prevalence and number of deaths due to COVID-19 and the possibility of a vaccine by the fall, we cannot lose sight of the bigger picture: the next pandemic.

Safety of Using Rituximab Therapy During COVID-19 Pandemic

Rituximab is a chimeric (20% rodent and 80% human) monoclonal antibody that binds to the CD20 antigen present on the cell surface and leads to depletion of mature B-cells [1,2]. It is the first approved monoclonal antibody to be used in the therapy of indolent B-cell non- Hodgkin’s lymphoma and chronic lymphocytic leukemia

Full Text
Cite
Download PDF
Author Information X

About Scientific Archives

Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.

Read More